Vivanza Biosciences Limited approved the convening of its 44th Annual General Meeting (AGM) and proposed amendments to its Memorandum of Association (MoA) and Articles of Association (AoA) during a board meeting held on August 17, 2026. The board also recommended that shareholders approve material related party transactions and an increase in the company’s borrowing limits for the financial year 2026-27.

The meeting, which took place at the company’s registered office in Ahmedabad, focused on statutory compliance and corporate governance updates. The directors approved the Director’s Report and Secretarial Audit Report for FY26. They also fixed September 4, 2026, as the cut-off date for determining member eligibility to attend and vote at the upcoming AGM via remote e-voting or poll.

Key Approvals

The board considered several proposals requiring shareholder consent under the Companies Act, 2013:

• Related Party Transactions: Approval for entering into material related party transactions during FY27.
• Borrowing Limits: Seeking permission under Section 180(1)(c) to increase borrowing limits beyond the aggregate of paid-up share capital, free reserves, and securities premium.
• Financial Transactions: Approval for loans, guarantees, or securities involving entities covered under Section 185 of the Companies Act, 2013.
• Investments: Seeking approval under Section 186 for making investments or granting loans in excess of prescribed limits.
• Constitutional Documents: Adoption of a new MoA and AoA aligned with the Companies Act, 2013.

Mr. Chintan K. Patel, a practicing company secretary, was appointed as the scrutinizer to oversee the e-voting and poll process for the AGM. The draft notice containing the day, date, time, and venue of the meeting was also issued.

What the Numbers Show

The source document is a regulatory disclosure regarding corporate actions and does not contain financial performance data such as revenue, profit, or cash flows. Consequently, no analytical observation regarding financial trends or metrics can be derived from this filing.

Vivanza Biosciences Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange. The filing, dated August 8, 2026, discloses that the company’s Board of Directors approved the financial statements on August 7, 2026, after they were reviewed by the Audit Committee. This submission ensures regulatory compliance and provides investors with updated performance metrics for the initial quarter of FY27.

The intimation was issued under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jayendra Amichand Mehta, Managing Director of Vivanza Biosciences, signed the communication to the Corporate Relationship Department at BSE Limited. The company also published extracts of the financial results along with the limited review report in The Indian Express (English) and Financial Express (Gujarati), adhering to disclosure norms for regional accessibility.

Financial Review Details

The filing confirms that the full format of the financial results is available on the stock exchange websites and the company’s official portal. While the specific numerical values for revenue, profit, or other key performance indicators are not detailed in this intimation letter, the document serves as a formal notification of the availability of these figures for stakeholder review.

Shareholder Information

Alongside the financial results, Vivanza Biosciences highlighted a special window for the transfer and dematerialization of physical securities. In accordance with SEBI Circular No. HO/38/13/11(2) 2026-MIRSD-POD/1/3750/2026, the special window has been extended from February 5, 2026, to February 4, 2027. This facility allows shareholders to re-lodge transfer requests for physical shares that were previously rejected or returned due to deficiencies in documents or processes prior to April 1, 2019.

Eligible shareholders must ensure their ledger has a demat account and provide a Client Master List (CML) along with transfer documents and share certificates. All transfers processed during this period will be issued only in dematerialized form. Shareholders are advised to contact the Registrar to the Issue and Share Transfer Agent (RTA), Purva Shareregistry (I) Ltd, for further assistance.